Synairgen Plc Banner Image

Synairgen Plc

  • Ticker SNG
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Synairgen Plc Logo Image
  • 11-50 Employees
  • Based in Southampton, England
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary diseaseMore exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
4.8 / 5.0 (106)

Synairgen Plc reports have an aggregate usefulness score of 4.8 based on 106 reviews.

Synairgen Plc

Most Recent Annual Report

Synairgen Plc
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Synairgen Plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!